Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

NCT00343044 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: Topotecan
DRUG: Bevacizumab

Sponsor

Benaroya Research Institute

Collaborators

[object Object]
[object Object]